AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Health officials reported that cases of human metapneumovirus (HMPV) spiked this spring as COVID-19 and Respiratory Syncytial Virus cases fell. National data from the Centers for Disease Control ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Study shows key role for human T cells in the control of Respiratory Syncytial Virus (RSV) infection Date: May 24, 2023 Source: University of North Carolina Health Care Summary: A new study has ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

WHAT WE FOUND Human Metapneumovirus (HMPV) is not new. The respiratory virus was first identified in 2001, according to the Centers for Disease Control and Prevention.

Research focuses on the design of a multi-epitope polyvalent vaccine against Human Respiratory Syncytial Virus (RSV), a leading cause of lower respiratory tract infections. The study utilizes ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

It is a seasonal disease that usually occur s in the winter and early spring, similar to Respiratory Syncytial Virus (RSV) and the flu. In the US, HMPV circulates in distinct annual seasons.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

But hMPV, which causes respiratory tract infections similar to colds and flu, is not new in China or elsewhere in the world and, as of Jan. 9, Chinese officials have not declared any emergency ...